| Literature DB >> 35216387 |
Encarnación Fuster1, Héctor Candela1, Jorge Estévez1, Eugenio Vilanova1, Miguel A Sogorb1.
Abstract
Quantum dots are nanoparticles with very promising biomedical applications. However, before these applications can be authorized, a complete toxicological assessment of quantum dots toxicity is needed. This work studied the effects of cadmium-selenium quantum dots on the transcriptome of T98G human glioblastoma cells. It was found that 72-h exposure to 40 µg/mL (a dose that reduces cell viability by less than 10%) alters the transcriptome of these cells in biological processes and molecular pathways, which address mainly neuroinflammation and hormonal control of hypothalamus via the gonadotropin-releasing hormone receptor. The biological significance of neuroinflammation alterations is still to be determined because, unlike studies performed with other nanomaterials, the expression of the genes encoding pro-inflammatory interleukins is down-regulated rather than up-regulated. The hormonal control alterations of the hypothalamus pose a new concern about a potential adverse effect of quantum dots on fertility. In any case, more studies are needed to clarify the biological relevance of these findings, and especially to assess the real risk of toxicity derived from quantum dots exposure appearing in physiologically relevant scenarios.Entities:
Keywords: T98G glioblastoma; gonadotropin-releasing hormone receptor pathway; in vitro; nanoparticles; nanosafety; neuroinflammation; quantum dots
Mesh:
Substances:
Year: 2022 PMID: 35216387 PMCID: PMC8877384 DOI: 10.3390/ijms23042267
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Physico-chemical properties of CdSe-QDs. Physical properties (panel (A)) and distribution of sizes as determined by DLS (panel (B)) and TEM (panel (C)). Panel (D) shows a picture of CdSe-QDs under TEM. Determinations were performed by Nanoimmunotech SL (https://nanoimmunotech.eu/en, accessed on 1 February 2022). DLS was analyzed in quintuplicate with a minimum of 10 runs per measurement. The Z-potential was analyzed in triplicate after adjusting the number of runs to each sample’s specific necessity.
Figure 2Analysis of the size and distribution of CdSe-QDs in water ((left) panels) and cell culture medium ((right) panels). Size was determined by DLS. The cell culture medium was the RPMI cellular medium supplemented with 10% FBS. DLS was analyzed in quintuplicate with a minimum of 10 runs per measurement. Determinations were performed by Nanoimmunotech SL (https://nanoimmunotech.eu/en accessed on 1 February 2022)).
Figure 3Effect of CdSe-QDs on the cell viability of the T98G human glioblastoma cells. T98G cells were exposed to different CdSe-QDs under the conditions described in Section 4.4. Cell culture viability was determined by the MTT test as described in Section 4.5. Each experimental condition was tested with six different wells of the same cell culture. Another independent experiment with an independent cell culture and six biological replicates per experimental condition yielded similar results. One hundred percent of viability was considered the viability of control (non-exposed) culture.
Effect of CdSe-QDs on the cell viability of the T98G human glioblastoma cells. The T98G human glioblastoma cells were exposed to NPs, as defined in Section 4.4 (Materials and Methods). Next, NPs were removed, and culture viability was determined by either the MTT or neutral red tests. The mean ± standard deviation of the percentage of viability for (n) independent experiments (run with independent cell cultures) is displayed. Each independent experiment was performed with six wells of the same cell culture. Each experiment was run simultaneously with a positive control of CuSO4 that reduced cell viability by around 80%.
| Concentration (µg/mL) | Test | % of Viability (n) |
|---|---|---|
| 40 | MTT | 89 ± 8 (9) |
| 30 | MTT | 91 ± 1 (3) |
| 40 | Neutral red | 96 ± 1 (7) |
Figure 4The T98G human glioblastoma cells visualized by TEM and SEM. T98G cells were exposed to 40 µg/mL of CdSe-QDs as described in Section 4.4 and then processed for the electronic microscopy assessment as set out in Section 4.6 according to the performing facility’s internal protocols. A second independent culture yielded similar results. The TEM pictures were obtained both at 37,000×. The SEM pictures were obtained at 8500× (control) and at 8000× (treated).
Alignment of the sequences to the reference genome. This experiment was run with CdSe-QDs in parallel with the experiments with titanium dioxide and zinc oxide NPs and, therefore, shares the controls with the data published by Fuster and coworkers [8].
| Control Samples | Treated Samples | |||||
|---|---|---|---|---|---|---|
| Replicate 1 | Replicate 2 | Replicate 3 | Replicate 1 | Replicate 2 | Replicate 3 | |
| Initial | 31,016,624 | 30,419,346 | 32,022,288 | 34,786,612 | 29,827,860 | 40,211,724 |
| Filtered | 26,681,128 | 26,192,232 | 26,451,976 | 29,101,028 | 24,773,250 | 36,251,964 |
| Aligned (%) | 26,342,795 | 25,793,274 | 26,083,336 | 28,717,867 | 24,455,042 | 35,782,526 |
| Duplicated (%) | 28.1 | 28.1 | 26.9 | 28.7 | 26.6 | 31.6 |
Figure 5Heat map of the differentially expressed genes in the control samples and the samples treated with CdSe-QDs. The Gene Cluster 3.0 software generated this map by selecting the Hierarchical Grouping option for the studied genes. Green represents under expression, while red annotates overexpression. The whole list of genes shown in this heat map, together with their respective fold changes and levels of statistical significance, are available in Supplementary Material Table S1.
The biological process ontology terms overrepresented in the differentially expressed genes in the T98G human glioblastoma cells exposed for 72 h to 40 µg/mL of CdSe-QDs. Only the results for FDR p < 0.05 are displayed. DEG = Differentially Expressed Genes; EF = Enrichment factor; FDR = False Discovery Rate.
| Biological Process | Genes in Reference List | Genes among DEG | Expected among DEG | EF | FDR | |
|---|---|---|---|---|---|---|
| Temperature homeostasis (GO:0001659) | 14 | 4 | 0.07 | 56 | 1.78 × 10−6 | 8.35 × 10−3 |
| Inflammatory response (GO:0006954) | 208 | 8 | 1.07 | 7.5 | 1.27 × 10−5 | 2.24 × 10−2 |
| Cytokine-mediated signaling pathway (GO:0019221) | 390 | 12 | 2.00 | 6.0 | 6.66 × 10−7 | 9.38 × 10−3 |
| Positive regulation of developmental process (GO:0051094) | 746 | 15 | 3.83 | 3.9 | 4.18 × 10−6 | 1.18 × 10−2 |
| Regulation of cell differentiation (GO:0045595) | 966 | 18 | 4.96 | 3.63 | 1.01 × 10−6 | 7.13 × 10−3 |
| Regulation of cell death (GO:0010941) | 1091 | 17 | 5.61 | 3.0 | 2.36 × 10−5 | 3.32 × 10−2 |
The reactome pathway ontology terms overrepresented in the differentially expressed genes in the T98G human glioblastoma cells exposed for 72 h to 40 µg/mL of CdSe-QDs. Only the results for FDR p < 0.05 are displayed. DEG = Differentially Expressed Genes; EF = Enrichment factor; FDR = False Discovery Rate.
| Reactome Pathway | Genes in Reference List | Genes among DEG | Expected among DEG | EF | FDR | |
|---|---|---|---|---|---|---|
| Interleukin-10 signaling | 16 | 3 | 0.08 | 36 | 1.16 × 10−4 | 4.92 × 10−2 |
| Interleukin-4 and Interleukin-13 signaling | 62 | 7 | 0.32 | 22 | 5.27 × 10−8 | 1.12 × 10−4 |
| Class A/1 (Rhodopsin-like receptors) | 50 | 5 | 0.26 | 19 | 8.36 × 10−6 | 8.87 × 10−3 |
Molecular pathways altered in the T98G human glioblastoma exposed for 72 h to 40 µg/mL of CdSe-QDs.
| Pathway | Genes | Log2 Fold Change |
|---|---|---|
| 5-Hydroxytryptamine degradation | Aldehyde dehydrogenase family 1 member A3 | 1.12 |
| Angiogenesis | Proto-oncogene c-fos | −2.16 |
| Tissue factor F3 ortholog | −1.05 | |
| Angiotensin II-stimulated signaling through G proteins and beta-arrestin | Early growth response protein 1 | −2.44 |
| Apoptosis signaling pathway | Proto-oncogene c-Fos | −2.16 |
| Baculoviral IAP repeat-containing protein 3 | −1.19 | |
| B cell activation | Proto-oncogene c-Fos | −2.16 |
| B-cell receptor CD22 | 1.41 | |
| Blood coagulation | Tissue factor F3 | −1.04 |
| CCKR signaling map | Early growth response protein 1 | −2.44 |
| Proto-oncogene c-Fos | −2.16 | |
| Interleukin-8 | −1.67 | |
| Substance-P receptor | 2.54 | |
| Baculoviral IAP repeat-containing protein 3 | −1.19 | |
| Coenzyme A biosynthesis | Pantothenate kinase 1 | 1.04 |
| Dopamine receptor-mediated signaling pathway | D(2) dopamine receptor | 1.07 |
| EGF receptor signaling pathway | Protein sprouty homolog 4 | −1.98 |
| FGF signaling pathway | Protein sprouty homolog 4 | −1.98 |
| Gonadotropin-releasing hormone receptor pathway | Early growth response protein 1 | −2.44 |
| Proto-oncogene c-Fos | −2.16 | |
| D(2) dopamine receptor | 1.07 | |
| DNA-binding protein inhibitor ID-3 | −1.07 | |
| Transcription factor jun-B | −1.16 | |
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha-mediated pathway | D(2) dopamine receptor | 1.07 |
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha-mediated pathway | D(2) dopamine receptor | 1.07 |
| B2 bradykinin receptor | 1.06 | |
| Huntington disease | Proto-oncogene c-Fos | −2.16 |
| Inflammation mediated by chemokine and cytokine signaling pathway | Interleukin-8 | −1.67 |
| Transcription factor jun-B | −1.16 | |
| Integrin alpha-M | −1.80 | |
| Interleukin-6 | −1.84 | |
| Interleukin-1 beta | 1.57 | |
| Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | Proto-oncogene c-Fos | −2.16 |
| Integrin signaling pathway | Integrin alpha-M | −1.80 |
| Interleukin signaling pathway | Proto-oncogene c-Fos | −2.16 |
| Interleukin-8 | −1.67 | |
| Interleukin-6 | −1.84 | |
| Nicotine pharmacodynamics pathway | D(2) dopamine receptor | 1.07 |
| PDGF signaling pathway | Proto-oncogene c-Fos | −2.16 |
| T cell activation | Proto-oncogene c-Fos | −2.16 |
| TGF-beta signaling pathway | Transcription factor jun-B | −1.16 |